Abstract:Abstract Objectives Rare diseases are a global public health issue with a more pressing situation in China. Unfortunately, the relevant research and development in this country are still in its infancy, leading to limited drug accessibility. In view of this, the Chinese government has taken a series of countermeasures to promote orphan drug R&D in recent years, which has presented encouraging results. This paper aims to review incentive policies and funding initiatives formulated by the Chinese government and examine their implications on orphan drug R&D. Methods Policies targeting orphan drug R&D during 2012–2022 were retrieved from the relevant official websites, categorized into different themes and analyzed for the contents. Data on government funding, drug approval, clinical trial approval and orphan drug designation were collected through internet search to analyze the implications of those incentive policies and initiatives on orphan drug R&D in China. Results A total of 20 relevant policy documents were identified and five major themes were revealed through content analysis, including national strategy, expedited approval, safety and efficacy requirements, data protection and technical support. The government input in orphan drug R&D has witnessed a steady annual increase. Driven by those incentives, the numbers of orphan drugs approved for marketing and drug candidates entering clinical studies are increasing year by year, and more domestic pharmaceutical companies are actively involved in the R&D of orphan drugs. Conclusions Orphan drug development in China is growing rapidly under the stimulation of incentive regulatory policies and more investment in researches. China is working toward a more standardized and comprehensive rare disease ecosystem. However, there are still some challenges, such as the lack of sufficient financial support and the call for systematic legislation on rare diseases, to be addressed for future success.

Research on Incentive Policies of Innovative Drugs in Japan and Its Enlightenment to China-an Empirical Study on Research and Development of Edaravone

International comparison of incentive policies for orphan drug and its enlightenment to China

The Comparative Study on Supervision and Incentive Policies of Sino-US During the Innovative Drug R&D

Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China

Comparing the Intellectual Property Financing Policies between China and Japan:A Case Study of Innovative Drugs' Patent-Pledging

Orphan drug regime in Japan and enlightenment on China: based on evaluation of orphan drug access in Japan

From Imitation to Innovation: A Study of China's Drug R&D and Relevant National Policies

The inspiration of the foreign innovation incentive system for orphan drug and its implication for China

The Research on Price Strategy to Incent China's Drug Innovation

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications

Research on policy environment of Japanese innovative drug——an empirical analysis based on thrombomodulin α

Research of Incentive Mechanism for the Essential Drug Manufacturers

Research on the link between expedited review and drug reevaluation from the perspective of innovation incentive based on American experience

A Cross-National Comparative Study of Orphan Drug Policies in the United States, the European Union, and Japan: Towards a Made-in-china Orphan Drug Policy.

Analysis on the Influence of Policy Factors in Innovating Behavior for Chinese Orphan Drugs’ Industry

Policy Updates on Access to and Affordability of Innovative Medicines in China.

Novel drug research and development ability in China: An international comparison and analysis

Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China

Study on the combined utilization of new drug expedited programs in America: the empirical analysis of osimertinib's R&D and application process

Enlightenment from Japan's Incentive Policy on Medical Device Access for Rare Diseases to China

Some Thoughts about the Improvement of Medical Treatment Insurance Policy to Promote Drug Innovation by Enterprises